Acadia Pharmaceuticals (NASDAQ: ACAD)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Acadia Pharmaceuticals Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Acadia Pharmaceuticals Company Info
The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
News & Analysis
Here are the five best biotech ETFs to invest in right now.
An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.
Regulators might be warming to the company's candidate to treat Alzheimer's-associated psychosis.
The biotech saw a rebound after a down day on Tuesday.
A positive clinical readout is lighting a fire underneath the biotech's shares today.
The overall index finally regained some lost ground.
An unexpected regulatory setback is weighing on the biotech's shares.
The good news? Sales of Nuplazid are soaring. The bad news? So is Acadia's spending.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/09/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
ACAD earnings call for the period ending November 8, 2021.
ACAD earnings call for the period ending June 30, 2021.
ACAD earnings call for the period ending March 31, 2020.
ACAD earnings call for the period ending December 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.